MedTrace Logo

Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases

NCT01070355 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2011-10-21

No results posted yet for this study

Summary

Eicosapentaenoic acid (EPA) is a naturally occuring omega-3 polyunsaturated fatty acid found in oily fish. EPA has anti-colorectal (bowel) cancer activity in experimental models. This trial will test whether EPA reduces markers of tumour growth, and is safe and well tolerated,in patients with colorectal cancer liver metastases awaiting surgery.

Conditions

Interventions

DRUG

Eicosapentaenoic acid free fatty acid

An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.

DRUG

Placebo

2 capsules taken twice daily for 2-6 weeks before liver resection.

Sponsors & Collaborators

  • University of Leeds

    lead OTHER

Principal Investigators

  • Mark A Hull, PhD, FRCP · Leeds Institute of Molecular Medicine, University of Leeds

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01070355 on ClinicalTrials.gov